RxDoctor Payments Data

Syed Ahmad

Rheumatology · Bluefield, VANPI 1487654182

Payments from drug & device makers

$4,455in general payments, 2019–2025

Across 271 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$755
  • AbbVie$597
  • Johnson & Johnson$428
  • Novartis$331
  • Mallinckrodt Hospital Products Inc.$266
  • plus $811 from 11 others

What the payments were for

  • Food & beverage$4,42499%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,455 in reported general payments places this provider in the 55th percentile of 159 rheumatology providers in Virginia.

See all rheumatology providers in Virginia

Medicare billing

Part B allowed, 2024
$98,564
Medicare patients
224
Services billed
3,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab136$943,985
Enbrel SureclickEtanercept121$937,763
RinvoqUpadacitinib92$652,380
Xeljanz XrTofacitinib Citrate64$372,368
EnbrelEtanercept25$308,749
Cosentyx Sensoready (2 Pens)Secukinumab33$242,999
Orencia ClickjectAbatacept23$158,066
OtezlaApremilast23$116,383
Humira(Cf)Adalimumab16$110,169
Humira PenAdalimumab13$102,324
Cimzia (2 Pack)Certolizumab Pegol11$73,039
XeljanzTofacitinib Citrate19$70,530
ProliaDenosumab34$58,816
Hydroxychloroquine Sulfate355$13,343
Leflunomide222$10,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Synthroid$597$764,196125 claims
AmgenEnbrel, Otezla, Prolia$1,268$483,94882 claims
UCB, Inc.Cimzia (2 Pack)$162$73,03911 claims
PfizerXeljanz$755$70,53019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 159 rheumatology providers in Virginia.

Other rheumatology in Bluefield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →